| 1.88 -0.08 (-4.08%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.69 |
1-year : | 3.01 |
| Resists | First : | 2.3 |
Second : | 2.57 |
| Pivot price | 2.24 |
|||
| Supports | First : | 1.87 |
Second : | 1.55 |
| MAs | MA(5) : | 2.04 |
MA(20) : | 2.26 |
| MA(100) : | 1.75  |
MA(250) : | 1.61 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 1.6 |
D(3) : | 4.3 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 2.57 | Low : | 1.17 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AUTL ] has closed below the lower bollinger band by 5.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ AUTL ] is to continue within current trading range. It is unclear right now based on current values. 45.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.99 - 2.01 | 2.01 - 2.02 |
| Low: | 1.83 - 1.85 | 1.85 - 1.87 |
| Close: | 1.85 - 1.89 | 1.89 - 1.92 |
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Sat, 12 Sep 2026
AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black - Yahoo Finance
Thu, 10 Sep 2026
Autolus Therapeutics (AUTL) Short Interest & Short Float | Updated Sep 2026 $AUTL - MarketBeat
Wed, 09 Sep 2026
A lupus cell therapy gets special FDA status. Testing continues. - Stock Titan
Sat, 05 Sep 2026
Autolus Therapeutics Stock Price Forecast. Should You Buy AUTL? - StockInvest.us
Fri, 28 Aug 2026
PPF reshuffles Autolus (NASDAQ: AUTL) stake without trimming exposure - Stock Titan
Fri, 14 Aug 2026
Autolus Therapeutics plc (NASDAQ:AUTL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 266 (M) |
| Held by Insiders | 3.39e+007 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 15,140 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.894e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 570.7 % |
| Return on Equity (ttm) | -22.3 % |
| Qtrly Rev. Growth | 1.08e+006 % |
| Gross Profit (p.s.) | -0.51 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -1 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 9.78 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.048e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|